Sept. 02, 2015
This talk portrays the pathway from a research hypothesis to a clinical therapy. Dr. John Mendelsohn, former president of the University of Texas MD Anderson Cancer Center, discusses his research studying the EGF receptor and how it led to the creation of the cancer drug Erbitux. He highlights the original hypothesis he and his collaborators were testing, why they came up with it and how it was tested. In addition, Mendelsohn describes how the drug was developed and its rocky road through clinical trials. Overall, the talk describes one man’s experience in translational medicine.